New long‑term results reinforce efficacy across AD and PN

Original title: “NEMLUVIO data show sustained three‑year responses in atopic dermatitis”

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now "less likely."

Original title: “BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival”

New option offers acute treatment for adults with migraine

Original title: “SMC accepts AQUIPTA for eligible migraine patients in Scotland”

Final analysis shows durable outcomes in MF and SS

Original title: “MINT study results strengthen real‑world evidence for mogamulizumab”

Dementia and Alzheimer's disease may be more common in women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), an association likely driven by metabolic comorbidities. (Journal of the Endocrine Society) The investigational enzyme replacement therapy efzimfotase alfa failed to hit its primary endpoint of improvement in the 6-Minute Walk Test in a phase III trial of treatment... Dementia and Alzheimer's disease may be more common in women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), an association likely driven by metabolic comorbidities. (Journal of the Endocrine Society) The investigational enzyme replacement therapy efzimfotase alfa failed to hit its primary endpoint of improvement in the 6-Minute Walk Test in a phase III trial of treatment-naive patients with hypophosphatasia, according to maker AstraZeneca. A low-fat plant-based diet was associated with improved liver fat content, insulin sensitivity, and beta-cell function in adults with type 2 diabetes in a single-arm trial. (BMJ Open Diabetes Research & Care) From 2017 to 2023, presentation rates for nonbinary youth increased 2.7-fold compared with binary transgender youth at an Australian pediatric gender clinic. Zealand Pharma said its investigational amylin analog petrelintide led to an average weight reduction of up to 9.2% at 28 weeks and with low discontinuation rates, compared with a 2% weight reduction with placebo, in a phase II trial of adults with overweight/obesity and type 2 diabetes. News and commentary from the endocrinology world

Original title: “Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued | MedPage Today”

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

Original title: “Bristol Myers dips on ‘confounding’ lung drug results”

A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.

Original title: “BMS’ Phase 3 win for lung drug clouded by high-dose miss”

First long‑acting therapy targeting root cause of ATTR‑CM

Original title: “SMC accepts vutrisiran for eligible patients in Scotland”

CVMP opinions on veterinary medicinal productsThe Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy…

Original title: “Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026”

The Multiple Sclerosis clinical trial analysis report delivers important insights into ongoing research on 75 pipeline Multiple Sclerosis Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US On October 08 2026 DelveInsight s Multiple Sclerosis Pipeline Insight 2026 ... The Multiple Sclerosis clinical trial analysis report delivers important insights into ongoing research on 75 pipeline Multiple Sclerosis Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US On October 08 2026 DelveInsight s Multiple Sclerosis Pipeline Insight 2026 report ... Multiple Sclerosis Emerging Drugs Profile * IMU-838: Immunic Therapeutics Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. TYK2 is a member of the Janus kinase (JAK) family involved in the signaling pathways of several pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and type I interferons, which are implicated in autoimmune and inflammatory diseases. By selectively inhibiting TYK2 without significantly affecting other JAK isoforms, CC-97540 aims to reduce inflammation with potentially fewer side effects compared to broader JAK inhibitors. It is being evaluated for use in conditions such as psoriasis and systemic lupus erythematosus. Currently, the drug is in Phase I stage of its clinical trial fo The market dynamics for Hereditary Transthyretin Amyloidosis (hATTR) are witnessing robust growth driven by increasing disease awareness, improvements in genetic testing and diagnosis, advancements in RNA-based gene-silencing therapies, and growing adoption of disease-modifying treatments. (Albany, New York) - October 08, 2026 - The market dynamics for Hereditary Transthyretin Amyloidosis (hATTR) are witnessing robust growth driven by increasing disease awareness, improvements in genetic testing and diagnosis, advancements in RNA-based gene-silencing therapies, and ... The Myelodysplastic Syndrome clinical trial analysis report delivers important insights into ongoing research on 120+ pipeline Myelodysplastic Syndrome Drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

Original title: “Multiple Sclerosis Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight”

The Myelodysplastic Syndrome clinical trial analysis report delivers important insights into ongoing research on 120 pipeline Myelodysplastic Syndrome Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US On October 08 2026 DelveInsight s Myelodysplastic Syndrome ... The Myelodysplastic Syndrome clinical trial analysis report delivers important insights into ongoing research on 120 pipeline Myelodysplastic Syndrome Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US On October 08 2026 DelveInsight s Myelodysplastic Syndrome Pipeline Insights 2026 report ... The market dynamics for Hereditary Transthyretin Amyloidosis (hATTR) are witnessing robust growth driven by increasing disease awareness, improvements in genetic testing and diagnosis, advancements in RNA-based gene-silencing therapies, and growing adoption of disease-modifying treatments. (Albany, New York) - October 08, 2026 - The market dynamics for Hereditary Transthyretin Amyloidosis (hATTR) are witnessing robust growth driven by increasing disease awareness, improvements in genetic testing and diagnosis, advancements in RNA-based gene-silencing therapies, and ... The Multiple Sclerosis clinical trial analysis report delivers important insights into ongoing research on 75+ pipeline Multiple Sclerosis Drugs, clinical strategies, upcoming therapeutics, and commercial analysis. Press release - ABNewswire - Myelodysplastic Syndrome Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 120+ Leading Players Wheeling the Therapeutics Landscape - published on openPR.com Currently, MNV-201 is undergoing a Phase I clinical trial (NCT06465160) that is actively recruiting participants. The study's primary objective is to evaluate the safety and therapeutic effects of MNV-201 in patients diagnosed with low-risk MDS. The Myelodysplastic Syndrome Pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Myelodysplastic Syndrome with aggregate therapies developed by each company for the same.

Original title: “Myelodysplastic Syndrome Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 120+ Leading Players Wheeling the Therapeutics Landscape”

The Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027…

Original title: “Clinical trial applications advice pilot becomes permanent”

After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo.

Original title: “Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold”

For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.

Original title: “Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers”